EU Aims to Unveil Plan to Tap Frozen Russian Assets Amid Doubts
The European Union is moving ahead with a proposal to tax profits from more than €200 billion ($218
2023-11-30 21:48
Turn Your Controller Into a Command Center – Introducing Turtle Beach’s Groundbreaking Designed for Xbox Stealth Ultra Wireless Controller
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:47
Cory Simpson Appointed CEO of Institute for Critical Infrastructure Technology (ICIT)
WASHINGTON--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:29
Beech-Nut Nutrition Company was Voted “Best Baby Food Brand” by 11k What to Expect Parents
AMSTERDAM, New York--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:23
Ford Lowers Profit Guidance as Labor Costs Rise $8.8 Billion
Ford Motor Co. restored financial guidance Thursday, saying profits would come in lower than earlier projections due to
2023-11-30 21:19
Renesas Unveils the First Generation of Own 32-bit RISC-V CPU Core Ahead of Competition
TOKYO--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:18
Lynn Smith joins National Bank of Coxsackie as VP/Chief Credit Officer
LATHAM, N.Y.--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:18
Thousands of fake Facebook accounts shut down by Meta were primed to polarize voters ahead of 2024
Meta says it has found and disabled thousands of fake Facebook accounts linked to China that were used to spread politically partisan content in the United States before next year’s election
2023-11-30 21:18
Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth
LONDON--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 21:16
Microsoft president says no chance of superintelligent AI soon
By Muvija M and Martin Coulter LONDON The president of tech giant Microsoft said there is no probability
2023-11-30 20:53
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market
2023-11-30 20:48
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
TORONTO--(BUSINESS WIRE)--Nov 30, 2023--
2023-11-30 20:48